BRIM-3

Vemurafenib in BRAF V600E-Mutant Metastatic Melanoma

Patient / Population Intervention / Exposition Comparaison Critère de jugement

In 675 patients with BRAF V600E-mutant unresectable or metastatic melanoma, vemurafenib improved overall survival compared with dacarbazine.

675

Schéma

Open-label RCT

Critère

Co-primary: overall survival and progression-free survival (OS interim analysis)

Pertinence

RésultatOS HR 0.37; PFS 5.3 vs 1.6 months (HR 0.26); ORR 48% vs 5%.

Chapman PB, et al. N Engl J Med. 2011;364(26):2507-2516. 10.1056/NEJMoa1103782

Discussion et critique

First BRAF inhibitor — proved the precision-oncology principle in melanoma. Resistance emerges quickly; BRAF+MEK combinations (COMBI-d/v) are now preferred.